NVentures

Nov 13, 2024

What You Should Know: –  Genesis Therapeutics , a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm. – This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023. Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery Genesis Therapeutics, an AI-focused biotechnology company headquartered in Burlingame, CA, is revolutionizing small molecule drug discovery through its proprietary generative and predictive AI platform, **GEMS (Genesis Exploration of Molecular Space)**. GEMS integrates cutting-edge AI methodologies, including language models, diffusion models, and physical machine learning (ML) simulations, to generate and optimize molecules targeting complex biological structures. Key Highlights of Genesis Therapeutics: – Advanced AI Integration:   – Enables the generation and optimization of molecules for intricate and high-impact targets. – Significant Funding and Growth:   – Developing a robust therapeutic pipeline addressing a variety of high-impact biological targets. – Strategic Collaboration with NVIDIA:   – Partnering with NVIDIA to enhance the efficiency of the GEMS platform. – Leveraging NVIDIA’s expertise to optimize computation for several neural network architectures crucial to drug discovery. – Focused on optimizing equivariant neural networks, which are essential for handling 3D geometric data such as protein and small molecule structures. – Integrated Operations:   – Ensures seamless synergy between AI-driven research and laboratory-based experimental validation. Through this collaboration, Genesis Therapeutics aims to accelerate its AI platform, making computational processes more efficient and enhancing the precision of drug discovery efforts. By leveraging NVIDIA’s technological expertise, Genesis is poised to advance its mission of developing novel therapeutics with greater accuracy and speed, ultimately addressing critical challenges in the biotechnology landscape. “We look forward to combining our expertise and resources with NVIDIA’s to help realize our vision of harnessing AI to generate breakthrough therapies for diseases with high unmet need,” said Evan Feinberg, Ph.D., founder and CEO of Genesis. “Addressing previously undruggable targets to create new medicines requires pioneering algorithms for drug discovery and fundamental infrastructure innovation. Working with NVIDIA, we will further the capabilities of our field-leading physical AI platform for structure-driven drug design.”